Clinical Trial Update: Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating abiraterone acetate and prednisone with or without veliparib in metastatic castration-resistant prostate cancer has completed; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• PREDNISONE (Prednisone)
• Veliparib (veliparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Castration-Resistant Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-11-12